Why Xylem Stock Is Back in Focus After Its New Wastewater Partnership

Xylem (XYL) is drawing fresh attention after Gross-Wen Technologies announced a commercial partnership that pairs Xylem’s anaerobic treatment platform with Gross-Wen’s algae based nutrient removal technology for industrial wastewater operators.

The agreement targets facilities facing tighter nutrient regulations and higher sustainability expectations, using a combined approach that addresses both organic loading and nutrient compliance in sectors that rely on anaerobic digestion processes.

Alongside the wastewater partnership news, Xylem’s share price has been relatively weak over 2026, with a year-to-date share price return of down 15.07%. The 1 year total shareholder return of down 8.01% contrasts with a 3 year total shareholder return of 7.26% and suggests momentum has cooled compared with earlier years.

If Xylem’s recent moves have you thinking about where water and infrastructure capital is heading next, it could be worth scanning 35 power grid technology and infrastructure stocks

With Xylem reporting annual revenue of US$9.1b and net income of US$981m, plus a market value around US$27.7b, the question is simple: is today’s weaker share price a genuine entry point, or is the market already paying up for future growth?

Most Popular Narrative: 22.7% Undervalued

On the numbers, the most followed narrative pegs Xylem’s fair value at $150.65 per share, well above the last close of $116.45. This is where the detailed story starts to matter.

Successful post-acquisition integration of Evoqua and revenue synergies from services expansion are accelerating Xylem's shift toward more recurring, higher-margin aftermarket and services revenue streams, boosting earnings stability and long-term profitability.

Want to see what justifies that higher fair value for Xylem? The narrative leans heavily on steady growth, fatter margins and a richer earnings multiple that assumes investors keep paying up for this profile.

Result: Fair Value of $150.65 (UNDERVALUED)

However, this Xylem narrative could be challenged if government infrastructure funding is slower than expected or if integration of acquisitions like Evoqua falls short.

Another View: Xylem Through The P/E Lens

The SWS DCF model points to Xylem trading below an estimated future cash flow value of $127.83 per share, yet the P/E story is less generous. At 28.2x earnings versus a fair ratio of 27.7x and a peer average of 42.5x, investors may be paying a full price for only modest upside.

Next Steps

If the mixed sentiment around Xylem has you undecided, it helps to see the data first hand and weigh it against your own expectations. To understand what investors are optimistic about, review the 5 key rewards

Looking For More Investment Ideas Beyond Xylem?

If Xylem has sharpened your focus on where to put fresh capital, do not stop with one stock. Widen your watchlist using targeted screeners built from real data.

• Target higher income potential with companies that feature durable payouts and yields by reviewing 8 dividend fortresses.
• Hunt for mispriced quality by scanning screener containing 19 high quality undiscovered gems before the wider market catches on.
• Prioritise resilience and smoother returns by filtering for 71 resilient stocks with low risk scores that can help steady your overall portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.